AACR: Personalized Vaccine for Cancer Tolerated, Feasible
Vaccine well tolerated in 13 patients; vaccine showed potential benefit in patients with solid tumors, multiple myeloma in phase 1 trial (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - April 12, 2021 Category: Cancer & Oncology Tags: Oncology, Pathology, Conference News, Source Type: news

FDA D.I.S.C.O. Burst Edition: FDA approval of ABECMA (idecabtagene vicleucel) the first FDA approved cell-based gene therapy for the treatment of adult patients with relapsed or refractory multiple myeloma
Listen to a soundcast of the March 26, 2021 FDA approval of ABECMA (idacabtagene vicleucel) the first cell-based gene therapy for treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA D.I.S.C.O. Burst: Approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adult patients with relapsed or refractory multiple myeloma who have received at least four lines of prior therapy
Listen to a soundcast of the February 26, 2021 FDA approval of Pepaxto (melphalan flufenamide) in combination with dexamethasone for adults patients with refractory multiple myeloma who received at least four prior lines of therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves isatuximab-irfc for multiple myeloma
Hematology / Oncology News (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 1, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Steroids Can Be Stopped in Some Older Myeloma Patients Steroids Can Be Stopped in Some Older Myeloma Patients
In intermediate-fit elderly patients newly diagnosed with multiple myeloma, dexamethasone can be stopped during maintenance without having an adverse effect on outcome.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA Approves Sarclisa (isatuximab-irfc) in Combination with Carfilzomib and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma
PARIS, March 31, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 31, 2021 Category: Drugs & Pharmacology Source Type: news

First Cell-Based Gene Therapy Approved for Multiple Myeloma
TUESDAY, March 30, 2021 -- Abecma (idecabtagene vicleucel), a chimeric antigen receptor (CAR) T-cell therapy, was approved by the U.S. Food and Drug Administration for the treatment of multiple myeloma, the agency announced Saturday. Abecma, a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 30, 2021 Category: Pharmaceuticals Source Type: news

FDA approves idecabtagene vicleucel for multiple myeloma
Hematology / Oncology News burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 29, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

First CAR T-Cell Therapy for Multiple Myeloma: Abecma First CAR T-Cell Therapy for Multiple Myeloma: Abecma
Idecabtagene vicleucel is the first chimeric antigen receptor (CAR) T-cell therapy to target B-cell maturation antigen, and the first to be approved for use in multiple myeloma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 29, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Abecma (idecabtagene vicleucel) as the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma
PRINCETON, N.J.,& CAMBRIDGE, Mass.--(BUSINESS WIRE) March 26, 2021 -- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 26, 2021 Category: Drugs & Pharmacology Source Type: news

One drop of blood brings progression of multiple myeloma into better view
(Radboud University Medical Center) A new method makes it much easier to follow the progression of multiple myeloma, a form of blood cancer. With a single drop of blood, it is possible to very accurately show whether the number of cancerous cells in the bone marrow is increasing in a patient. In time, this blood test could potentially replace the current bone marrow puncture. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 26, 2021 Category: Cancer & Oncology Source Type: news

Mayo Clinic Minute: What is multiple myeloma?
Multiple myeloma is a relatively uncommon form of blood cancer that affects less than 1% of the U.S. population, according the American Cancer Society. People younger than 45 rarely get the disease, and it occurs more in older men than women. And your risk is doubled if you're African American. Watch: The Mayo Clinic Minute [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - March 25, 2021 Category: Databases & Libraries Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
Progression - free, three - year overall survival similar for lenalidomide maintenance regimen without dexamethasone (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 24, 2021 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Geriatrics, Journal, Source Type: news

Maintenance Therapy Without Steroids Feasible in Elderly Myeloma Patients
WEDNESDAY, March 24, 2021 -- Dose/schedule-adjusted lenalidomide-dexamethasone (Rd) followed by a maintenance regimen of lenalidomide 10 mg/day without dexamethasone (Rd-R) is feasible for older patients with multiple myeloma (MM), with survival... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2021 Category: Pharmaceuticals Source Type: news

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
SOUTH SAN FRANCISCO, Calif., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering... Biopharmaceuticals, Oncology, Personnel Sutro Biopharma, XpressCF+, multiple myeloma, non-Hodgkin lymphoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news

CLAIRE GILBERT: Are doctors asking us cancer patients to suffer too much?
CLAIRE GILBERT: Seven weeks after that phone call, it is confirmed: I have myeloma, a cancer affecting the white blood cells. My prognosis is I will die in about ten years. (Source: the Mail online | Health)
Source: the Mail online | Health - March 15, 2021 Category: Consumer Health News Source Type: news

Guidance Offered for Improving Diversity in Multiple Myeloma Trials
Ways to improve representation of African Americans in clinical trials could be extrapolated to other underrepresented groups (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 10, 2021 Category: Cancer & Oncology Tags: Oncology, Journal, Source Type: news

Guidance Offered for Improving Diversity in Multiple Myeloma Trials
WEDNESDAY, March 10, 2021 -- In an initiative from the Dana-Farber Cancer Institute in Boston, the U.S. Food and Drug Administration, and the American Association for Cancer Research, published online Feb. 18 in Blood Cancer Discovery,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 10, 2021 Category: Pharmaceuticals Source Type: news

New CAR T-Cell therapy extends remission in heavily relapsed multiple myeloma patients
(UT Southwestern Medical Center) A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 8, 2021 Category: International Medicine & Public Health Source Type: news

' Phenomenal' Results with CAR T-Cells in R/R Multiple Myeloma'Phenomenal' Results with CAR T-Cells in R/R Multiple Myeloma
In a heavily pretreated population of patients with relapsed/refractory myeloma, CAR-T cell therapy generated deep, sustained remissions and prolonged progression-free survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 3, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

FDA grants accelerated approval to melphalan flufenamide for relapsed or refractory multiple myeloma
Hematology / Oncology News Burst (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 1, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Pepaxto (melphalan flufenamide) for Patients with Relapsed or Refractory Multiple Myeloma
STOCKHOLM, Feb. 26, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2021 Category: Drugs & Pharmacology Source Type: news

CAR T-cell therapy generates lasting remissions in patients with multiple myeloma
(Dana-Farber Cancer Institute) In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 24, 2021 Category: Cancer & Oncology Source Type: news

New recommendations aim to eliminate racial bias in myeloma trials
(Dana-Farber Cancer Institute) Recommendations designed to address the under-representation of African Americans in clinical trials for multiple myeloma (MM), a blood cancer that is twice as deadly in this demographic as in whites. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 18, 2021 Category: International Medicine & Public Health Source Type: news

Metabolic response behind reduced cancer cell growth
(Uppsala University) Researchers from Uppsala University show in a new study that inhibition of the protein EZH2 can reduce the growth of cancer cells in the blood cancer multiple myeloma. The reduction is caused by changes in the cancer cells' metabolism. These changes can be used as markers to discriminate whether a patient would respond to treatment by EZH2 inhibition. The study has been published in the journalCell Death& Disease. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 12, 2021 Category: Biology Source Type: news

Medication-based starvation of cancer cells
(Technical University of Munich (TUM)) Immunomodulatory drugs, including the Contergan derivatives lenalidomide and pomalidomide have significantly improved the therapy of hematologic malignancies such as multiple myeloma. Researchers at the Technical University of Munich (TUM) have now further decoded the mode of action in this class of medications. At the same time, they identified new innovative targeted cancer therapies. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 12, 2021 Category: Cancer & Oncology Source Type: news

Cutaneous Involvement in Plasma Cell Myeloma Cutaneous Involvement in Plasma Cell Myeloma
This study highlights the histopathologic findings and the differential diagnostic considerations for plasma cell neoplasms in skin.American Journal of Clinical Pathology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 10, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

CART T Elicits Strong Response for Multiple Myeloma
For patients with heavily-pretreated multiple myeloma, the strong responses seen with the new CAR T-cell treatment have also been prolonged. (Source: WebMD Health)
Source: WebMD Health - February 8, 2021 Category: Consumer Health News Source Type: news

ICER releases Draft Evidence Report on multiple myeloma therapies
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

Plitidepsin Could Treat COVID-19, Preclinical Data Suggest Plitidepsin Could Treat COVID-19, Preclinical Data Suggest
Early evidence for plitidepsin, an antiviral that has been studied for the treatment of multiple myeloma, could be repurposed as a therapy against COVID-19.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - January 28, 2021 Category: Drugs & Pharmacology Tags: Infectious Diseases News Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

In preclinical models, antiviral better inhibits COVID-19 than Remdesivir; further studies warranted
(American Association for the Advancement of Science) Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 25, 2021 Category: International Medicine & Public Health Source Type: news

Renal Insufficiency May Worsen Multiple Myeloma Outcomes
Risk for disease progression or death increased for those with renal insufficiency in relapsed/refractory, newly diagnosed MM (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - January 22, 2021 Category: Cancer & Oncology Tags: Nephrology, Oncology, Journal, Source Type: news

Renal Insufficiency May Worsen Multiple Myeloma Outcomes
FRIDAY, Jan. 22, 2021 -- For patients with multiple myeloma (MM), those with renal insufficiency (RI) have an increased risk for disease progression or death, according to a systematic review and meta-analysis published online Jan. 8 in Leukemia... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 22, 2021 Category: Pharmaceuticals Source Type: news

Whole body imaging detects myeloma in more patients, treatment initiated earlier
(King's College London) Researchers from King's College London have shown that whole body magnetic resonance imaging (WBMRI) not only detects more myeloma-defining disease than positron emission tomography/computed tomography (PET/CT) with 18F-fluorodeoxyglucose (FDG) but that it also allows critical treatment to be initiated earlier. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 21, 2021 Category: Cancer & Oncology Source Type: news

Designer DNA therapeutic wipes out cancer stem cells, treats multiple myeloma in mice
(University of California - San Diego) UC San Diego study supports launch of Phase I clinical trial to test a designer DNA agent -- an antisense oligonucleotide that targets a gene called IRF4 -- in patients with multiple myeloma. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - January 20, 2021 Category: Biology Source Type: news

Expert Alert: What's on the horizon for multiple myeloma and other blood cancers
ROCHESTER, Minnesota -- World Cancer Day is Feb. 4, 2021, highlighting how everyone can help reduce the global burden of cancer. In 2018, there were 17.0 million new cancer cases and 9.5 million cancer deaths worldwide. The three major types of blood cancer are leukemia, lymphoma and myeloma. Multiple myeloma is a cancer that forms [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - January 20, 2021 Category: Databases & Libraries Source Type: news

DARZALEX FASPRO ® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 15, 2021 (HORSHAM, Pa.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) approval of DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj), a subcutaneous formulation of daratumumab, in combination with bortezomib, cyclophosphamide and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis.[1] DARZALEX FASPRO® is the first and only FDA-approved treatment for patients with this blood cell disorder that is associated with the production of an abnormal protein, which leads to th...
Source: Johnson and Johnson - January 16, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Advances in Multiple Myeloma From ASH 2020 Advances in Multiple Myeloma From ASH 2020
Breakthroughs in multiple myeloma from ASH 2020 include transplant studies in newly diagnosed patients, triple therapy in early relapse, and CAR T-cell as well as bispecific therapy in later relapse.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 28, 2020 Category: Consumer Health News Tags: None ReCAP Source Type: news

Janssen Initiates Rolling Submission of a Biologics License Application to U.S. FDA for BCMA CAR-T Therapy Ciltacabtagene Autoleucel (cilta-cel) for the Treatment of Relapsed and/or Refractory Multiple Myeloma
December 21, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the initiation of a rolling submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ciltacabtagene autoleucel (cilta-cel), an investigational B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy, for the treatment of adults with relapsed and/or refractory multiple myeloma.“We are committed to innovation in cell therapy and advancing the science of multiple myeloma to improve patients’ lives,” said Pete...
Source: Johnson and Johnson - December 21, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

FDA approves selinexor for refractory or relapsed multiple myeloma
On December 18, 2020, the Food and Drug Administration approved selinexor (XPOVIO, Karyopharm Therapeutics Inc.) in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - December 18, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Karyopharm Announces FDA Approval of Xpovio (selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy
NEWTON, Mass., Dec. 18, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial stage pharmaceutical company pioneering novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has approved... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 18, 2020 Category: Drugs & Pharmacology Source Type: news

$10 million gift supports new myeloma research center at Ohio State
(Ohio State University Wexner Medical Center) The OSUCCC - James has received a $10 million gift from the Paula and Rodger Riney Foundation to establish the Riney Family Foundation Myeloma Center for Advanced Research Excellence. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 17, 2020 Category: Cancer & Oncology Source Type: news

Durable Responses With Anti-BCMA CAR T-cell for Multiple Myeloma Durable Responses With Anti-BCMA CAR T-cell for Multiple Myeloma
For patients with heavily-pretreated multiple myeloma, responses seen with the novel chimeric antigen receptor T-cell construct ciltacabtagene autoleucel (cilta-cel) have also been durable.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma Five-Minute SC Injection of Daratumumab in R/R Multiple Myeloma
The subcutaneous formulation of daratumumab in combination with pomalidomide and dexamethasone showed significant improvement in progression-free survival.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 9, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
Subcutaneous daratumumab plus pomalidomide and dexamethasone reduces risk of progression, death in relapsed/refractory MM (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 8, 2020 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Conference News, Source Type: news

ASH: Adding Subcutaneous Daratumumab Slows Advanced Multiple Myeloma
TUESDAY, Dec. 8, 2020 -- For patients with relapsed/refractory multiple myeloma (RRMM), subcutaneous daratumumab plus pomalidomide and dexamethasone (D-Pd) reduces the risk of progression or death compared with Pd alone, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2020 Category: Pharmaceuticals Source Type: news

Fixed Duration Ibrutinib/Venetoclax Feasible for Some CLL/SLL Fixed Duration Ibrutinib/Venetoclax Feasible for Some CLL/SLL
For patients with heavily pretreated multiple myeloma, responses seen with the novel chimeric antigen receptor T-cell (CAR T-cell) construct ciltacabtagene autoleucel have also been durable.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 8, 2020 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

New treatment uncovered for AL amyloidosis to be announced at ASH Meeting
(SWOG) Researchers from SWOG Cancer Research Network, a cancer clinical trials group funded by the National Cancer Institute (NCI), part of the National Institutes of Health, have shown that isatuximab, a monoclonal antibody approved for the treatment of multiple myeloma, can effectively treat relapsed refractory AL amyloidosis, findings to be announced at the 2020 Annual Meeting of the American Society of Hematology (ASH), held virtually December 5-8, 2020. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 7, 2020 Category: Cancer & Oncology Source Type: news

Janssen Presents First Data from the Phase 1 Study of the GPRC5DxCD3 Bispecific Talquetamab in Patients with Relapsed or Refractory Multiple Myeloma
December 5, 2020 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial data for the Phase 1 first-in-human dose escalation study of talquetamab (JNJ-64407564) for the treatment of relapsed or refractory multiple myeloma (NCT03399799). Talquetamab is a first-in-class, and the only investigational bispecific antibody that targets both GPRC5D, a novel multiple myeloma target, and CD3 on T-cells. Initial results for both the subcutaneous (SC) and intravenous (IV) formulations show encouraging clinical activity against the GPRC5D target, which is highly expressed on multip...
Source: Johnson and Johnson - December 5, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news